Arcturus Therapeutics (NASDAQ: ARCT)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Arcturus Therapeutics Returns vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Arcturus Therapeutics Company Info
Arcturus Therapeutics Holdings Inc.
News & Analysis
Investors liked what they heard in its Q4 update.
Investors are applauding Arcturus' collaboration with CSL.
It's not likely, but it could still end up being a good investment.
The biotech stock climbed more than $5 a share in early trading Thursday.
The company disappointed last year, but things may be turning around.
The company received a green light to advance two COVID-19 vaccine candidates into clinical testing in a second country.
There's at least one biotech that appears to be a potential contender.
Only if its COVID-19 vaccine proves to be at least as effective than those developed by its rivals.
Motley Fool Returns
Market-beating stocks from our award-winning analyst team.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 03/31/2023.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.